News | Contrast Media | August 14, 2020

FDA Approves Gadavist (gadobutrol) Imaging Bulk Package

The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite

The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite

August 14, 2020 — The U.S. Food and Drug Administration (FDA) announced the approval of the Gadavist (gadobutrol) Imaging Bulk Package. The Gadavist Imaging Bulk Package will be available in two presentation sizes, 30 mL and 65 mLand allows for weight-based dosing with a 24-hour stand time for multi-patient dosing.

In conjunction with the bulk package approval, the FDA also cleared the MEDRAD Imaging Bulk Package Transfer Spike that is indicated for the transfer of Gadavist contrast media as supplied in the Imaging Bulk Package presentation.

As the only MR contrast media FDA-approved Imaging Bulk Package for use with a cleared transfer spike, Gadavist Imaging Bulk Package offers key features to support the radiology workflow. After initial set up, the product can be used across multiple patients and work shifts for up to 24 hours after the first puncture of the Imaging Bulk Package. Compared to single-use bottles, the Imaging Bulk Package can potentially mean more complete usage of the contrast and less contrast and vial waste. In addition, technologists and nurses can prepare and administer weight-based dosing using a single multi-dose set up directly in the scan room. The bulk package adheres to the Joint Commission requirements for multi-patient dosing.1

“With the changing healthcare environment, Bayer is dedicated to investing not only in new innovations, but aligning our solutions to address some of the challenges that hospitals are facing today,” said Dennis Durmis, Head of Region Americas, Bayer Radiology. "We are focused on offering solutions in new areas of unmet need."

Sentinel Event Alert 52: Preventing infection from the misuse of vials. The Joint Comission web site. https://www.jointcommission.org/en/resources/patient-safety-topics/sentinel-event/sentinel-event-alert-newsletters/sentinel-event-alert-issue-52-preventing-infection-from-the-misuse-of-vials/. Accessed August 11, 2020.

For more information: www.bayer.com

Related Content

Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...
Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. #AI #AIhealthcare #AIecho

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
January 6, 2021 — The U.S.
Now, researchers using magnetic resonance imaging (MRI) have found potential brain biomarkers of PTSD in people with traumatic brain injury (TBI).
News | Magnetic Resonance Imaging (MRI) | December 31, 2020
December 31, 2020 — Posttraumatic stress disorder (...
Researchers at the University of Turku have discovered what type of neural mechanisms are the basis for emotional responses to music. Altogether 102 research subjects listened to music that evokes emotions while their brain function was scanned with functional magnetic resonance imaging (fMRI). The study was carried out in the national PET Centre.

Getty Images

News | Magnetic Resonance Imaging (MRI) | December 30, 2020
December 30, 2020 — Researchers at the University of Turku have di
This novel agent, based on the essential nutrient manganese, has strong potential as a safer alternative to currently used contrast agents
News | Contrast Media | December 28, 2020
December 28, 2020 — Adding a contrast-enhancing agent to...
All but 3 of the top 25 articles in 2020 were on COVID-19. The other 3 were on MRI contrast advances and the development of a cold-cathode X-ray tube technology. #COVID19

All but 3 of the top 25 articles in 2020 were on COVID-19. The other 3 were on MRI contrast advances and the development of a cold-cathode X-ray tube technology.

Feature | December 23, 2020 | Dave Fornell, Editor
Here are the top 25 best performing articles on the Imaging Technology News (ITN) website from 2020.